Disease-modifying immunotherapy for the management of autoimmune diabetes

CASTRO, CN; BARCALA TABARROZI, AE; ANTUNICA NOGUEROL, M; LIBERMAN, AC; DEWEY, RA; ARZT, E; MORELLI, AE; PERONE, MJ

NEUROIMMUNOMODULATION.

KARGER

Año: 2010 vol. 17 p. 173 - 176

1021-7401

Type 1 diabetes (T1D) is a T cell-mediated autoimmune diseasethat destroys the insulin-secreting  -cells of the pancreas.It is now possible to predict those candidates that willprogress to T1D before the full onset of the disease. Preventionof uncontrollable autoimmunity against  -cells in therapiesfor T1D is mandatory to preserve the  -cell mass.Therefore, immunomodulatory strategies directed to inhibitingthe activity of self-reactive T cell clones as well as inductionof regulatory T cells would be beneficial for preventionof T1D or recurrence of  -cell autoimmunity against islet cellallografts.